Welcome to Pathway to Prescriptions
If you’ve ever wondered why a seemingly promising drug never reaches your clinic, or why an old, familiar molecule suddenly appears with a new indication and a very different price tag, you’re in the right place. Pathway to Prescription is for healthcare professionals who want a clear view of how medicines really move from idea to first prescription—and beyond.
Each week, I’ll unpack the journey from molecule to medicine in plain, clinically grounded language, so you can see how upstream decisions in R&D, regulation, commercialisation, and supply show up in your day‑to‑day practice.
Who I am (and why I’m doing this)
I’ve spent my career inside the pharmaceutical and supply‑chain world: working with manufacturers, contract partners, and regulators on how drugs are developed, scaled up, and kept (or not kept) on shelves. I’ve seen how trial design, CMC headaches, pricing decisions, and fragile supply chains translate into the very practical questions you face in clinics, MDTs, and formulary meetings.
Pathway to Prescription exists to bridge that gap. My aim isn’t to sell products or push corporate narratives, but to decode the processes and incentives behind the medicines you prescribe, dispense, or commission—so you can interpret evidence, policy, and industry messaging with more confidence.
The 5 big stages between idea and first prescription
For most medicines, the journey from “interesting idea” to a script written in clinic runs through five big stages. The details vary by therapy area and product, but the pattern is remarkably consistent.
1. From target to lead compound
It starts with a biological target and a hypothesis: if we modulate this receptor, pathway, or mechanism, we might change the course of disease. Researchers screen and optimise potential compounds (or biologics) to find a candidate that looks potent, selective, and developable.
For HCPs, this stage is largely invisible, but it shapes almost everything that follows: the eventual mechanism of action, likely on‑target and off‑target effects, and the sort of patients who might benefit—or be harmed.
2. Preclinical development and early risk checks
Promising candidates move into preclinical studies to answer basic questions on safety, pharmacology, and how the drug behaves in the body (ADME). Formulation, stability, and manufacturability start to matter: can this actually be made at scale, in a form patients will use?
Most molecules die here. The ones that move forward carry early safety and pharmacology assumptions into first‑in‑human studies—and those assumptions explain a lot of what you later see in early clinical data and SmPC wording.
3. Clinical trials: phases I–III
Once the first‑in‑human hurdle is cleared, the familiar phase I–III progression begins:
Phase I: small numbers, safety, tolerability, dose‑finding, PK in humans.
Phase II: proof of concept and dose‑ranging in the target population.
Phase III: larger, confirmatory studies designed to support regulatory approval.
Trial design choices here—endpoints, comparators, inclusion/exclusion criteria—are where the future “real‑world” questions start. When you later ask “but what about older patients, multiple comorbidities, or different ethnic groups?”, the answer often lies in decisions taken at this stage.
4. Regulatory review and approval
Regulatory agencies review the totality of evidence (quality, non‑clinical, clinical) and decide whether the benefit–risk profile justifies approval for specific indications, doses, and patient populations. They may also impose risk‑management plans, post‑marketing study requirements, or restrictions on use.
For HCPs, this is where the formal label and SmPC emerge: which patients are “on‑label”, what monitoring is expected, and what uncertainties regulators still want answered. The time lag between trial read‑out, regulatory decision, and local commissioning is often where frustration builds.
5. Market access, supply, and the first prescription
Approval is not the end of the story. Payers and HTA bodies assess cost‑effectiveness, budget impact, and place in therapy. Pricing, access schemes, and contracting determine whether and how quickly the drug can be added to local formularies and pathways.
In parallel, manufacturing and supply chains are scaled up (or sometimes stretched) to meet demand. This is where real‑world delays, stock issues, and “we’re still waiting on a funding decision” arise—the gap between a licensed medicine and a drug you can actually prescribe with confidence.
Where repurposing fits in
Drug repurposing and new indications essentially “re‑enter” this pathway at various stages. An existing molecule might jump straight to a phase II proof‑of‑concept in a new disease area, or move through an abridged regulatory route based on prior knowledge and safety data.
From your side of the desk, that can look like:
An old generic suddenly gaining a new, niche indication.
A cancer drug migrating into new tumour types or lines of therapy.
A medicine you know well appearing in guidelines in a very different context.
A big part of what I’ll do in Pathway to Prescription is show how and why those repurposing journeys succeed—or stall—and what that means for practice, budgets, and patient conversations.
What’s coming next
Over the next few weeks, you can expect:
A deeper dive into why “it takes so long”: timelines, attrition, and where delays really happen.
A practical guide to reading pivotal trial headlines with a supply‑chain and regulatory lens.
A walkthrough of how a repurposed drug moves from idea to guideline recommendation.
A case‑based look at how manufacturing and contracting decisions become the shortages you see on the ward.
Each issue will be designed to be read in 10–15 minutes, with clear headings and takeaway points you can use in MDTs, governance meetings, journal clubs, or conversations with patients and colleagues.
How you can shape this
I’d like this to be genuinely useful in your world, not just interesting background reading.
If you have 30 seconds, hit reply and tell me:
Your role (e.g. registrar, consultant, pharmacist, manager, nurse specialist), and
One question you have about how drugs are developed, repurposed, approved, or funded.
I’ll use your questions to prioritise future issues and case studies.
Thanks for joining me on the Pathway to Prescription.
Good luck with the new venture. I am sure it would be useful to medical students who will have been taught that all pharma is good.